Our Team

Michael Kubica

Michael is Founder and President of MedTech Valuation, Inc. Michael has two decades of experience in providing quantitative analysis, forecasting and financial valuation solutions for leading pharmaceutical, biotechnology, medical device and diagnostics companies. 

 

Prior to establishing MedTech Valuation, Michael Held the position of Vice President, Operations for Magellan Health Services. During his career Michael has also held positions of Vice President of Quality Management, Regional Director of Business Operations & Finance, and Hospital Administrator.

 

Michael has held the academic post of Adjunct Professor of Finance. Statistics and Research Methods at St. Thomas University in Miami, FL.

Michael holds a Master’s of Science in Business Administration (MBA) and a Master’s Degree in Psychology.

 

Eric Misenheimer

 

Eric Misenheimer has combined accounting and investment experience of over 35 years.  Over the course of his career, he has worked for privately held companies, a top ranked accounting firm (Price Waterhouse ) and also managed top ranked mutual funds of up to $1.2 billion in assets mostly specializing in high yield, fixed income debt.  He has reviewed and analyzed a significant number of industries and companies throughout his career.  His knowledge of valuations and business models has enabled him to assist both investors and companies in better understanding their specific opportunities.

Eric's skills, talents and opinions have been featured in many publications including the Wall Street Journal, Money Magazine, Barron's and Forbes. He holds the C.P.A. designation. 

 

Eric holds a B.A. degree in Accounting and an M.S. degree in Finance from Loyola College in Baltimore, Maryland.

Shelly Cropper


Ramesh has over 12 years experience as a life science industry consultant specializing in market analysis, strategic forecasting and valuation of medical technologies.  During his career he has held positions in strategic finance for Intuitive Surgical, Life Science Equity Research Associate at JP Morgan, Associate at Extera Partners and Consultant at Easton Associates.

 

He is particularly skilled at structuring financial arrangements enabling licensing, merger and acquisition deals.



Ramesh Donthamsetty

Ramesh has over 12 years experience as a life science industry consultant specializing in market analysis, strategic forecasting and valuation of medical technologies.  During his career he has held positions in strategic finance for Intuitive Surgical, Life Science Equity Research Associate at JP Morgan, Associate at Extera Partners and Consultant at Easton Associates.

 

He is particularly skilled at structuring financial arrangements enabling licensing, merger and acquisition deals.

 

Eric Misenheimer

 

Eric Misenheimer has combined accounting and investment experience of over 35 years.  Over the course of his career, he has worked for privately held companies, a top ranked accounting firm (Price Waterhouse ) and also managed top ranked mutual funds of up to $1.2 billion in assets mostly specializing in high yield, fixed income debt.  He has reviewed and analyzed a significant number of industries and companies throughout his career.  His knowledge of valuations and business models has enabled him to assist both investors and companies in better understanding their specific opportunities.

Eric's skills, talents and opinions have been featured in many publications including the Wall Street Journal, Money Magazine, Barron's and Forbes. He holds the C.P.A. designation. 

 

Eric holds a B.A. degree in Accounting and an M.S. degree in Finance from Loyola College in Baltimore, Maryland.

Ramesh Donthamsetty


Ramesh has over 12 years experience as a life science industry consultant specializing in market analysis, strategic forecasting and valuation of medical technologies.  During his career he has held positions in strategic finance for Intuitive Surgical, Life Science Equity Research Associate at JP Morgan, Associate at Extera Partners and Consultant at Easton Associates.

 

He is particularly skilled at structuring financial arrangements enabling licensing, merger and acquisition deals.



© 2017. MedTech Valuation, Inc.  All rights reserved.